actinium-225 labeled daratumumab (Actinium Pharmaceuticals)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug Nameactinium-225 labeled daratumumab (Actinium Pharmaceuticals)
Drug Alias Nameactinium-225 conjugated monoclonal antibody (Actinium/MSKCC)Actinium Ac 225-DOTA-Daratumumab225Ac-DOTA-daratumumab[225Ac]-DOTA-Daratumumab225Ac-Daratumumab +[6] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsHematologic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesActinium Pharmaceuticals IncCity Of Hope National Medical CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteCity Of Hope National Medical CenterActinium Pharmaceuticals Inc
Inactive CompaniesMemorial Sloan Kettering Cancer Center
Active IndicationsMultiple Myeloma
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A